The latest purported Apple Glass leaks are the most detailed to date on what might be Apple's next big product.
There's an update for your Surface Pro 4 that improves stability and security. What you need to know The Surface Pro 4 has a new firmware update. As usual, the update includes stability improvements and security updates. The updates should be available thr…
First quarter continued to demonstrate success of the recurring revenue model Organization focused on advancing stress urinary incontinence clinical strategy Company to host conference call at 5:00 PM ...
NEW YORK, NY / ACCESSWIRE / March 19, 2020 / Viveve Medical, Inc. (NASDAQ:VIVE) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 19, 2020 at 5:00 ...
Companies in the news are: NVAX, UBER, CSS, VIVE
A big jump, but if you were expecting a jolt that would "save" the PC-VR space, well...
Companies in the news are: NVCN, VIVE, SDRL, UROV
ENGLEWOOD, CO / ACCESSWIRE / March 4, 2020 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, announced today that it has completed enrollment in its three-arm, three-month feasibility study to compare Viveve's Cryogen-cooled Monopolar Radiofrequency (CMRF) treatment and a cryogen-only sham treatment to an inert sham treatment for the improvement of stress urinary incontinence (SUI) in women. The Investigational Testing Application (ITA) study, approved by the Canadian Ministry of Health, was initiated in January 2020.
Some retailers have inventory again. Here's where you can find the so-hot-it-won't-stay-in-stock $400 VR headset.
ENGLEWOOD, CO / ACCESSWIRE / April 16, 2020 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced it has received regulatory clearance from the Canadian Ministry of Health for the Company's next-generation Viveve 2.0 Cryogen-cooled Monopolar Radiofrequency (CMRF) system and consumable treatment tips for improvement of sexual function in women following vaginal childbirth. "We are very pleased to have received regulatory clearance of the Viveve 2.0 System from Health Canada, which we believe is another confirmation of the proven efficacy and safety profile of our innovative technology in the treatment of women's intimate health conditions," said Scott Durbin, chief executive officer of Viveve.
But you'll have to convince your mates to part with $599 for 5G-enabled Mova XRSpace, a startup founded by one-time HTC chief Peter Chau, has announced plans to introduce a new 5G-enabled virtual-reality headset in Q3 of this year.…
ENGLEWOOD, CO / ACCESSWIRE / April 17, 2020 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today provided a company update, including plans to significantly reduce operating expenses and cash burn rate, steps to strengthen its balance sheet and reconfirmation of near-term focus to advance development program for the treatment of stress urinary incontinence (SUI) in women. "Today we have taken important steps towards preserving and creating long-term value by adjusting our commercial activities to focus on our existing customers while retaining the ability to re-scale commercial growth quickly in the future, preserving cash and strengthening our balance sheet to focus on our fully enrolled SUI clinical trial in the midst of the COVID-19 crisis," said Scott Durbin, Viveve's chief executive officer.
ENGLEWOOD, CO / ACCESSWIRE / December 31, 2019 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, announced today that it has been notified by Nasdaq that Viveve has regained compliance with the Nasdaq Capital Market continued listing requirements, the scheduled hearing before the Nasdaq Hearings Panel has been cancelled, and Viveve will continue to trade on the Nasdaq Capital Market. Viveve Medical, Inc. is a medical technology company focused on women's intimate health. In the United States, the Viveve System is cleared by the U.S. Food and Drug Administration (FDA) for use in general surgical procedures for electrocoagulation and hemostasis.
ENGLEWOOD, CO / ACCESSWIRE / March 6, 2020 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced that it will provide a corporate update and report its year-end 2019 financial results after the close of the U.S. financial markets on Thursday, March 19, 2020. The Company will host a conference call and webcast at 5:00 PM ET the same day. A recording of the webcast will be posted on the Company's investor relations website following the call at ir.viveve.com and will be available online for 90 days.
Let's dive into a collection of buried treasure available on Xbox Game Pass. Microsoft recently revealed that Xbox Game Pass has surpassed 10 million users. To celebrate this massive milestone we'll be showcasing 10 hidden gems on the service you probably ha…
Good news, Oculus Rift S hunters. Stock levels for Oculus’s best VR headset have shot back up over at Overclockers UK today, marking the first time anyone’s been able to get hold of the headset in absolutely ages.
Unlike the Oculus Rift S, the Oculus Quest doesn’t technically need a PC in order to play VR games. Instead, it’s a standalone VR headset that you can play completely wire-free without having a great big gaming PC at your disposal. Naturally, this means it’s …
ENGLEWOOD, CO / ACCESSWIRE / April 15, 2020 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, announced today that the company has resubmitted its Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) for approval to begin a stress urinary incontinence (SUI) multicenter, randomized, double-blinded, sham-controlled trial now entitled, PURSUIT - Prospective U.S. Radiofrequency SUI Trial. The trial is designed to evaluate the safety and efficacy of Viveve's CMRF treatment versus an inert sham tip for the improvement of SUI in women.
ENGLEWOOD, CO / ACCESSWIRE / January 14, 2020 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, announced today that it has initiated enrollment in its three-arm, three-month feasibility study to compare Viveve's cryogen-cooled monopolar radiofrequency (CMRF) treatment and a cryogen-only sham to an inert sham treatment for the improvement of stress urinary incontinence (SUI) in women. Approval of the Investigational Testing Application from the Canadian Ministry of Health to conduct the study was reported in mid-December 2019.
ENGLEWOOD, CO / ACCESSWIRE / March 12, 2020 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, announced today that all patients have now completed participation in the VIVEVE II pivotal FDA clinical trial. VIVEVE II is a multicenter, randomized, double-blinded, sham-controlled study to evaluate the safety and efficacy of the Company's proprietary, Cryogen-cooled Monopolar Radiofrequency (CMRF) technology for the improvement of sexual function in women following vaginal childbirth. An estimated 12-14 million women worldwide suffer from diminished sexual function following vaginal childbirth who are candidates for our treatment.
Company completes successful U.S. commercial transition from traditional capital sales model to recurring revenue rental model Landmark pivotal sexual function trial (VIVEVE II) completed with data readout ...
The latest purported Apple Glass leaks are the most detailed to date on what might be Apple's next big product.
Microsoft's Mixed Reality Dev Days will be inside AltspaceVR, a popular app for meeting within virtual reality. What you need to know Microsoft opened registration for Mixed Reality Dev Days. The event will be hosted inside AltspaceVR, a VR app available…
Q4 2019 Viveve Medical Inc Earnings Call
Last year, HP released one of the world’s highest resolution VR headsets in the HP Reverb, but sadly, it was only really intended for use by enterprise customers. But for the new Reverb G2, HP partnered with Valve to create an upgraded HMD meant for both busi…
Hundreds of millions of people are taking online meetings from home due to the coronavirus lockdowns. And now they can do it in virtual reality. On Thursday, HTC announced its Vive Sync platform for business meetings in virtual reality is now in open beta. T…
In an era of social distancing, apps like Bigscreen present an amazing opportunity to stay close to the ones we love but can't be with, whether they're across town or across the country. Bigscreen transforms your living room into a social gathering space, all…
Between 2014 and 2019, Google and its Android licensees promoted various smartphone-based virtual reality systems. At the same time, Apple remained conspicuously absent from the smartphone VR headset race, which in hindsight appears prescient. Here's a look a…
Eye-tracking, wireless PC streaming, and a 4K display for under $1,000. Pico is pivoting to an enterprise-only strategy with its second-generation Neo VR headsets. The Pico Neo 2 and Pico Neo 2 Eye are standalone VR HMDs (head-mounted displays) that were u…
Video game designer Sos Sosowski has been working on his Mosh Pit Simulator game since 2016. Here's the official game description: Mosh Pit Simulator is a VR game about a world that is overrun by brainless boneless humanoid creatures due to a terrible acciden…
President of the American Medical Association, Dr. Patrice Harris speaks with Yahoo Finance's Anjalee Khemlani about the COVID-19 pandemic. Dr. Harris breaks down the stimulus package making its way through Congress as well as how the healthcare landscape will change for the future after the pandemic ends.
Eye-tracking, wireless PC streaming, and a 4K display for under $1,000. Pico is pivoting to an enterprise-only strategy with its second-generation Neo VR headsets. The Pico Neo 2 and Pico Neo 2 Eye are standalone VR HMDs (head-mounted displays) that were u…
ENGLEWOOD, CO / ACCESSWIRE / May 7, 2020 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced that it will provide a corporate update and report its first quarter 2020 financial results after the close of the U.S. financial markets on Thursday, May 14, 2020. The Company will host a conference call and webcast at 5:00 PM ET the same day. A recording of the webcast will be posted on the Company's investor relations website following the call at ir.viveve.com and will be available online for 90 days.
Quest Quest's new hands-free hand-tracking is here. How does it work? We try it out with Walt of the Wizard, a VR game with hand-tracking.
ENGLEWOOD, CO / ACCESSWIRE / March 26, 2020 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced registration clearance from the Taiwanese Food and Drug Administration for the Company's next-generation Viveve 2.0 Cryogen-cooled Monopolar Radiofrequency (CMRF) system and consumable treatment tips for use in general surgical procedures for electrocoagulation and hemostasis. "We are also pleased to continue our support of Dynamic Medical Technologies, Inc., our exclusive distribution partner in Taiwan, and their efforts to advance clinician adoption and utilization of Viveve's innovative technology platform for the treatment of women's intimate health conditions."
ENGLEWOOD, CO / ACCESSWIRE / April 17, 2020 / Viveve Medical, Inc. ("Viveve") (VIVE), a medical technology company focused on women's intimate health, today announced that it has entered into agreements with several institutional and accredited investors to exercise certain outstanding Series A warrants to purchase an aggregate of up to 4,820,584 shares of common stock and Series B warrants to purchase an aggregate of up to 242,790 shares of common stock raising gross proceeds of approximately $3 million. Viveve also announced the reduction in the exercise price of its Series A warrants and Series B warrants from $1.55 per share to $0.61.
ENGLEWOOD, CO / ACCESSWIRE / April 9, 2020 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced topline results from the VIVEVE II clinical trial. VIVEVE II is a multicenter, randomized, double-blinded, sham-controlled study to evaluate the safety and efficacy of the company's proprietary, Cryogen-cooled Monopolar Radiofrequency (CMRF) technology for the improvement of sexual function in women following vaginal childbirth. The VIVEVE II study did not meet its primary endpoint of demonstrating a statistically significant improvement in the mean change from baseline in total Female Sexual Function Index (FSFI) score at 12 months.
When the Oculus Rift S offers a pretty darn great VR experience for £399 / $399, is there really any reason to spend upwards of a grand on a headset like the £919 / $999 Valve Index? Probably not if, like the rest of us, you don’t have a spare mattress full o…
Dan Carlin narrates an immersive VR ride through WWI trenches and skies. From developer, Flight School Studio, and publisher, MWM Interactive, comes War Remains: Dan Carlin Presents an Immersive Memory. It's an unforgettable history lesson and a horrific gli…
Benzinga Pro's Stocks To Watch For Wednesday Bellerophon (BLPH) - Following a nearly 170% rally to close Tuesday's session, Bellerophon shares pulled back about 5% to under the $9 level Wednesday morning. ...